Our two lead programs have completed Phase 1 – VENT-02, a brain-penetrant NLRP3 inhibitor, and VENT-03, a first-in-class cGAS inhibitor.
We are a clinical-stage biopharmaceutical company leveraging our machine learning-enabled ReSOLVE™ platform to advance a pipeline of novel medicines in immunology, inflammation, and neurology.